Part,  Chapter, Paragraph

 1   II,     5.  1.  1|       susceptible individuals.~ ~· Parkinson’s Disease~The cause of the
 2   II,     5.  1.  1|       neurodegenerative process of Parkinson’s Diseases is still unknown.~ ~·
 3   II,     5.  5.  3|         Multiple System Atrophy~PD~Parkinson’s disease~PSP~Progressive
 4   II,     5.  5.  3|                           5.5.3.6. Parkinson’s disease~ ~ ~
 5   II,     5.  5.  3|            5.3.6.1. Introduction~ ~Parkinson’s disease (PD) is one of
 6   II,     5.  5.  3| contributing to its burden (Global Parkinson’s Disease Survey Steering
 7   II,     5.  5.  3|           total number of cases of Parkinson’s disease in Europe~ ~Figure
 8   II,     5.  5.  3|           total number of cases of Parkinson’s disease in selected EUGLOREH
 9   II,     5.  5.  3|            1. Incidence studies of Parkinson’s disease in Europe.~ ~Crude
10   II,     5.  5.  3|           2. Prevalence studies of Parkinson’s disease in Europe.~ ~Estimates
11   II,     5.  5.  3|           5.3.6.3. Distribution of Parkinson’s disease cases according
12   II,     5.  5.  3|           5.3.6.3. Distribution of Parkinson’s disease cases according
13   II,     5.  5.  3|          in those patients (Global Parkinson’s Disease Survey Steering
14   II,     5.  5.  3|          Figure 5.5.3.6.3. Cost of Parkinson’s disease stratified by
15   II,     5.  5.  3|       neurodegenerative process in Parkinson’s disease is still unknown.
16   II,     5.  5.  3|            Purely genetic forms of Parkinson’s disease have been identified,
17   II,     5.  5.  3|          with a decreased risk for Parkinson’s disease (Elbaz and Tranchant,
18   II,     5.  5.  3|        with increased or decreased Parkinson’s disease risk, but the
19   II,     5.  5.  3|         Commission for people with Parkinson’s disease. Most plans and
20   II,     5.  5.  3|           Diagnosis and Therapy of Parkinson’s Disease - was a multinational
21   II,     5.  5.  3|            clinically well defined Parkinson’s disease out-patients,
22   II,     5.  5.  3|           and patient utilities of Parkinson’s disease. (EuroPa Consortium,
23   II,     5.  5.  3|       Andlin-Sobocki et al, 2005). Parkinson’s disease has been selected
24   II,     5.  5.  3|          nursing home placement in Parkinson’s disease: a population-based,
25   II,     5.  5.  3|           in prevalence surveys of Parkinson’s disease. Mov Disord 13(
26   II,     5.  5.  3|          1999): Dietary factors in Parkinson’s disease: the role of food
27   II,     5.  5.  3|     Amaducci L, Inzitari D (2000): Parkinson’s disease and parkinsonism
28   II,     5.  5.  3|           JF (2004): Prevalence of Parkinson’s disease and other types
29   II,     5.  5.  3|        2006): Nongenetic causes of Parkinson’s disease. Journal of neural
30   II,     5.  5.  3|            D (1998): Prevalence of Parkinson’s disease in Northwestern
31   II,     5.  5.  3|              The health burdens of Parkinson’s disease. Mov Disord 13(
32   II,     5.  5.  3|        Quality of life and care in Parkinson’s disease. Br J Clin Pract
33   II,     5.  5.  3|            J (2002): Prevalence of Parkinson’s disease in Cantalejo,
34   II,     5.  5.  3|            D (1987): Prevalence of Parkinson’s disease in the Republic
35   II,     5.  5.  3|            A (1995): Prevalence of Parkinson’s disease in the elderly:
36   II,     5.  5.  3|     Prevalence of parkinsonism and Parkinson’s disease in Europe: the
37   II,     5.  5.  3|      Action on the Epidemiology of Parkinson’s disease. Journal of neurology,
38   II,     5.  5.  3|             The economic impact of Parkinson’s disease. An estimation
39   II,     5.  5.  3|    Projected number of people with Parkinson disease in the most populous
40   II,     5.  5.  3|        life and economic impact of Parkinson’s disease. Drugs Aging 23(
41   II,     5.  5.  3|    mortality and cause of death in Parkinson disease. Versicherungsmedizin /
42   II,     5.  5.  3|         environmental exposures in Parkinson's disease. J Neurol Sci.
43   II,     5.  5.  3|            J (1999): Prevalence of Parkinson’s disease in lower Aragon,
44   II,     5.  5.  3|           for Clinical Research of Parkinson’s Disease. Moving Along
45   II,     5.  5.  3|        Epidemiology and therapy of Parkinson disease in inpatient nursing
46   II,     5.  5.  3|            influencing the risk of Parkinson's disease: a case-control
47   II,     5.  5.  3|          Direct economic impact of Parkinson’s disease: a research survey
48   II,     5.  5.  3|          Update on the genetics of Parkinson’s disease. Mov Disord 22
49   II,     5.  5.  3|          Suppl 17:S343-350.~Global Parkinson’s Disease Survey Steering
50   II,     5.  5.  3|    impacting on quality of life in Parkinson’s disease: results from
51   II,     5.  5.  3|         home placement in advanced Parkinson’s disease. Neurology 43(
52   II,     5.  5.  3|    Peterson EL (1999): Smoking and Parkinson’s disease: a dose-response
53   II,     5.  5.  3|          Multiple risk factors for Parkinson’s disease. J Neurol Sci
54   II,     5.  5.  3|          VC, De Bastiani P (1991): Parkinson’s disease in Ferrara, Italy,
55   II,     5.  5.  3|        sydney multicentre study of Parkinson’s disease: progression and
56   II,     5.  5.  3|        Sydney Multicenter Study of Parkinson’s disease: non-L-dopa-responsive
57   II,     5.  5.  3|             The natural history of Parkinson’s disease in the pre-levodopa
58   II,     5.  5.  3|          therapeutic management of Parkinson’s disease. Report of a joint
59   II,     5.  5.  3|           I: early (uncomplicated) Parkinson’s disease. Eur J Neurol
60   II,     5.  5.  3|            diagnosis of idiopathic Parkinson’s disease: a clinico-pathological
61   II,     5.  5.  3|     environmental risk factors for Parkinson’s disease. Parkinsonism
62   II,     5.  5.  3|            of French patients with Parkinson’s disease. Pharmacoeconomics
63   II,     5.  5.  3|            Dodel R (2005): Cost of Parkinson’s disease in Europe. Eur
64   II,     5.  5.  3|      environmental risk factors in Parkinson disease: what is the evidence?
65   II,     5.  5.  3|             Predicting the cost of Parkinson’s disease. Mov Disord 22(
66   II,     5.  5.  3|        Paterson JG, Roy SK (1986): Parkinson’s disease in a Scottish
67   II,     5.  5.  3|            A (2003): Prevalence of Parkinson’s disease: a door-to-door
68   II,     5.  5.  3|              Smoking, nicotine and Parkinson’s disease. Trends Neurosci
69   II,     5.  5.  3|           patients with idiopathic Parkinson’s disease : Results from
70   II,     5.  5.  3|           Study on Epidemiology of Parkinson’s Disease with Dementia (
71   II,     5.  5.  3|            1979): The frequency of Parkinson’s disease in the Province
72   II,     5.  5.  3|      Devoto MC (1980): The risk of Parkinson disease in Mediterranean
73   II,     5.  5.  3|          and motor fluctuations in Parkinson’s disease. A community-based
74   II,     5.  5.  3|             1973): Social costs of Parkinson’s disease. J Chronic Dis
75   II,     5.  5.  3|     illness and its predictors for Parkinson’s disease in Germany. Pharmacoeconomics
76   II,     5.  5.  3|            B, McQuillan WJ (1985): Parkinson’s disease in the district
77   II,     5.  5.  3|             2000): Epidemiology of Parkinson’s disease and akinetic syndromes.
78   II,     5.  5.  3|             2003): Is the cause of Parkinson’s disease environmental
79   II,     5.  5.  3|            of incidence studies of Parkinson’s disease. Mov Disord 18(
80   II,     5.  5.  3|         and survival in idiopathic Parkinson’s disease: Olmsted County
81   II,     5.  5.  3|        incidence and prevalence of Parkinson’s disease in the elderly
82   II,     5.  5.  3|        Prevalence and incidence of Parkinson’s disease in Europe. Eur
83   II,     5.  5.  3|            M (1997): The burden of Parkinson’s disease on society, family,
84   II,     5.  5.  3|           HY~Hoehn & Yahr scale~PD~Parkinson’s disease~SMR~Standardized
85  Key,   Ap5.  0.  0|     paratyphi~paratyphoid~parental~parkinson~particles~particulate~pathogens~